Becton Dickinson Pays $22M To Settle Syringe Antitrust Suits

Law360, Los Angeles (August 1, 2013, 8:24 PM EDT) -- Becton Dickinson & Co. has struck a $22 million settlement agreement with hospitals and pharmacies whose class actions accused the New Jersey-based medical technology company of stifling competition from other hypodermic product makers, the company said in a Tuesday filing with the U.S. Securities and Exchange Commission.

Under the terms of the proposed settlement, BD will pay $22 million into a settlement fund in exchange for a release by all potential members of the class of indirect purchasers of BD products, which alleged the company controlled...
To view the full article, register now.